Tunisian Pharmaceutical Industries Company Siphat Resumes Industrial Activities
The Tunisian Ministry of Health has announced the restart of the liquid medicine production chain at Siphat, the Tunisian pharmaceutical industries company, after several years of inactivity.
Resumption of Medication Production
This resumption includes the production of medications in syrup form, such as Hexabain, as well as antacids and several other pharmaceutical products. According to the Ministry, this revival aims to improve the availability of essential medications on the Tunisian market and strengthen national production capacities. The authorities specify that this restart was carried out in accordance with international quality and pharmaceutical safety standards.
Progress in Industrial Relaunch
This new stage follows the gradual resumption of several other production lines within Siphat, including dry forms, suppositories, and physiological serum. The government seeks to restore this public company's strategic role in the Tunisian pharmaceutical industry. In its statement, the Ministry of Health also praised the efforts of the company's executives, technicians, and workers, highlighting their commitment to this recovery process.
Siphat's Revival and Pharmaceutical Sovereignty
Created to support the country's pharmaceutical sovereignty, Siphat is now attempting to gradually regain its position among the main national players in the pharmaceutical sector. With this industrial relaunch, Siphat is taking a significant step towards strengthening Tunisia's pharmaceutical industry and improving access to essential medications for its population.
